Company Insights

OGEN supplier relationships

Explore interactive graphBrowse insights index
OGEN supplier relationship map

Oragenics (OGEN): Supplier map and what it means for investors

Oragenics is a clinical-stage biotechnology company that develops intranasal therapeutics for neurological disorders and retains legacy antibiotic programs; it monetizes by advancing candidates through clinical trials toward out-licensing or commercialization while financing operations through equity placements and short-term capital instruments. The company's operating model is heavily outsourced: manufacturing, clinical execution, regulatory strategy and discovery augmentation are managed by third parties, and capital is raised through at‑the‑market sales and placement agents. For a concise supplier posture and relationship readout, see more at https://nullexposure.com/.

How Oragenics structures development and supply — the operating thesis

Oragenics runs a lean, outsourced development engine. Clinical development, drug substance/product manufacture, IND/regulatory preparation and early discovery are contracted to specialized partners, which keeps fixed costs low but creates concentration and operational dependency. Financially, the company is small-cap (Market Capitalization approximately $3.3M) with negative EBITDA and zero trailing revenue, so third‑party suppliers and placement agents are critical to sustain forward programs.

Company-level operating signals drawn from filings and press releases:

  • Short-term financing posture: the firm has used short-dated notes with significant original issue discounts and maturity tied to subsequent offerings, signaling reliance on bridge-style capital.
  • Geographic footprint includes APAC: Phase 1 work occurred in Melbourne, Australia, showing willingness to run clinical work outside the U.S. when appropriate.
  • Critical supplier concentration: Oragenics discloses a sole-source supplier for ONP-002 drug substance/product, creating a material single‑point operational risk.
  • Manufacturer role outsourced: the company outsources synthetic chemistry and cGMP manufacturing rather than maintaining in‑house capacity.
  • Service provider reliance: placement agents and CROs are active parts of the go-to-market and development pathway.
  • Active relationship stage: multiple partnerships and an ATM arrangement are currently live and being executed.

The partner roster, one line each (what they do and why it matters)

Below is every relationship captured in recent public reporting, with a short plain-English summary and source.

  • Receptor.AI — Oragenics formed a strategic collaboration to use Receptor.AI’s platform to accelerate AI-driven drug discovery for neurological indications, expanding the pipeline beyond its lead concussion program. This was announced across company press releases and financial news in FY2025–FY2026 (GlobeNewswire Feb 2026; Lethbridge Herald Nov 2025).
    Source: GlobeNewswire (Feb 9, 2026) and Lethbridge Herald (Nov 12, 2025).

  • Southern Star Research — Selected as the Clinical Research Organization (CRO) for the upcoming Phase 2a trial of ONP-002, giving Oragenics an external partner to run trial operations. The selection is detailed in company releases covering FY2025–FY2026.
    Source: GlobeNewswire (Feb 9, 2026) and Yahoo Finance (Mar 2026 coverage).

  • Sterling Pharma Solutions — Contracted for FDA cGMP manufacturing in Cary, North Carolina after moving manufacturing out of China, indicating a U.S.-based supply chain for cGMP drug substance/product work. This change is described in the company’s February 2026 announcements.
    Source: GlobeNewswire (Feb 9, 2026) and Yahoo Finance (Mar 2026).

  • Intrexon Corporation (XON) — Oragenics holds an exclusive worldwide license to AG013 from Intrexon for treatment of oral mucositis (OM) in cancer patients, a legacy licensing relationship documented in an SEC filing from FY2017.
    Source: SEC filing (Exhibit to 2017 filing).

  • DUCK FLATS Pharma / Duck Flats Pharma — Engaged as the U.S. IND readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design for Oragenics’ intranasal concussion program, a relationship announced in February 2026.
    Source: GlobeNewswire (Feb 3, 2026) and distribution on Yahoo Finance (Feb 2026).

  • Dawson James Securities Inc. — Acts as placement agent under an At-The-Market (ATM) sales agreement that Oragenics amended on January 22, 2026, enabling the company to issue and sell shares over time for liquidity and financing. This is a capital markets relationship, not a development partner.
    Source: Press release reporting via The Globe and Mail (Jan 22, 2026).

  • Avance Clinical — Named as a CRO partner in prior commentary and described by company executives as a collaborator on Phase II trial activities, reflecting multiple CRO engagements across programs.
    Source: CityBiz reporting on executive appointments and company comments (FY2024 coverage).

  • Odyssey Health Inc. — Oragenics completed an acquisition of assets from Odyssey Health, adding proprietary neurological drug therapies and technologies to its pipeline and augmenting in‑house assets. This M&A step was reported in early 2024.
    Source: Healio news (Jan 3, 2024).

(Each relationship summary above is drawn from company press releases, SEC disclosure and coverage from financial news outlets between 2017 and early 2026.)

For a consolidated view of Oragenics’ supplier relationships and risk profile, visit https://nullexposure.com/.

What these relationships reveal about risk and optionality

Oragenics’ partner set shows a classic small‑biotech trade-off: low fixed cost and fast scalability in return for execution concentration risk. Key investor implications:

  • Operational concentration is material. The company discloses a sole-source supplier for ONP-002 and no redundant second source; that creates a direct production risk if the named manufacturer or supplier experiences disruption. This is a material company-level constraint disclosed in filings.
  • Onshoring manufacturing reduces geopolitical exposure but does not eliminate supplier concentration; contracting Sterling Pharma in North Carolina reduces China-related logistic risk but centralizes manufacturing to a new single partner.
  • CRO strategy is flexible and layered. Multiple CRO engagements — Avance Clinical, Southern Star Research — suggest Oragenics is willing to select providers by trial phase and geography, which improves program execution options.
  • Discovery diversification via Receptor.AI and M&A. The Receptor.AI collaboration and the Odyssey Health asset purchase broaden discovery and pipeline generation beyond the single lead program, increasing long‑term optionality.
  • Financing is dilutive and reactive. The company’s ATM with Dawson James and the existence of short-term note structures indicate reliance on equity and bridge financing, which creates dilution risk that investors must price into the equity.

Mid‑article action: for a full supplier risk scorecard and continuous monitoring of Oragenics’ partners, go to https://nullexposure.com/.

What investors should monitor next

  • Supplier redundancy and backup manufacturing: track whether Oragenics secures secondary manufacturers or raw material sources for ONP-002.
  • CRO performance and timelines: successful Phase 2a execution with Southern Star Research will materially re‑rate program risk.
  • Regulatory milestones from Duck Flats/IND readiness: IND acceptance and trial design outcomes set near-term value inflection points.
  • Capital raising cadence and dilution: watch ATM activity and any new note issuances for equity dilution and runway implications.
  • Progress in AI discovery and M&A integration: Receptor.AI outputs and Odyssey Health asset development will determine whether pipeline diversification translates into realistic clinical candidates.

Bottom line and investor steps

Oragenics operates an outsourced, capital-dependent development model with meaningful concentration risk but expanding discovery optionality courtesy of AI partnerships and recent M&A. Investors should weigh the upside from a successful Phase 2a and AI-augmented pipeline against the operational hazard of a single-source supplier and ongoing dilution through AMT/placement financings.

If you want a supplier-level diligence package or a supplier concentration heat map for Oragenics and its peer group, visit https://nullexposure.com/ for detailed coverage and monitoring tools.